Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof

• US 9,725,697 B2
• Filed: 05/11/2015
• Issued: 08/08/2017
• Est. Priority Date: 04/08/2010
• Status: Expired due to Fees

• Current Assignee: University of Edinburgh
• Original Assignee: University of Edinburgh
• Inventors: Pier, David Matthew, Noble, Brendon Stewart
• Primary Examiner(s): Bertoglio, Valarie
• Application Number:
  US14/708,606
• Publication Number:
  US 20150240208A1
• Time in Patent Office: 820 Days
• CPC Class Codes: A61K 35/32 Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/84 from mammals
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/03 from non-embryonic pluripotent stem cells
• CPC Class Codes: C12N 5/0655 Chondrocytes; Cartilage
• CPC Class Codes: C12N 5/0662 Stem cells
• CPC Class Codes: G01N 33/5044 involving specific cell types

Abstract

The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.

Claims

1. A population of de-differentiated committed chondrocyte precursor cells, wherein the de-differentiated committed chondrocyte precursor cells are the in vitro progeny of human embryonic stem (hES) cells and characterized by 85% or more of the cells expressing CBFA1 and by the loss of transdifferentiation potential to form osteoblasts when cultured in osteogenic medium.

2. The population of claim 1, wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60.

3. The population of claim 1, wherein 1% or less of the cells express Ki67.

4. The population of claim 1, further comprising human embryonic stem (hES) cells, wherein the de-differentiated committed chondrocyte precursor cells are the in vitro progeny of the hES cells.

5. A first and a second population of cells, comprising:

a) a first in vitro population of cells comprising human embryonic stem (hES) cells; and

b) a second in vitro population of cells comprising de-differentiated committed chondrocyte precursor (DDPC) cells that are the progeny of the hES cells, wherein 85% or more of the DDPCs express CBFA1 and wherein the DDPCs are characterized by the loss of transdifferentiation potential to form osteoblasts when cultured in osteogenic medium.